Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 13 de 13
Filter
1.
Drug Metab Dispos ; 44(11): 1771-1779, 2016 11.
Article in English | MEDLINE | ID: mdl-27538916

ABSTRACT

The crystal structures of human CYP2B6 indicate that Phe206 and Val367 are in close proximity to the substrate binding site and suggest that both residues may play important roles in substrate metabolism and inhibitor binding. To test this hypothesis, we investigated the effects of mutating these residues to Ala on the regiospecificity of CYP2B6 for the metabolism of testosterone and androstenedione. For testosterone metabolism, 16ß-OH-testosterone formation by the F206A mutant was <5% of the wild type (WT), whereas the V367A mutant exhibited a doubling of 16α-OH-testosterone formation with a 50% decrease in 16ß-OH-testosterone formation compared with the WT. Significant alterations in the regiospecificity for androstenedione metabolism were also observed. To investigate the roles of these two residues in the metabolic activation of mechanism-based inactivators, tert-butylphenylacetylene (BPA) and bergamottin (BG) were used to test the susceptibility to inactivation. Although the rates of inactivation of both mutants by BG were not significantly decreased compared with the WT, the efficiency of inactivation by BPA of both mutants was more than an order of magnitude lower. Our results demonstrate that Phe206 plays a crucial role in determining the specificity of CYP2B6 for the 16ß-hydroxylation of testosterone and androstenedione and that it also plays an important role in BG binding and mechanism-based inactivation by BPA. In addition, Val367 dramatically enhances the catalytic activity of CYP2B6 toward androstenedione and plays an important role in mechanism-based inactivation by BPA. The results presented here show the important roles of Phe206 and Val367 in interactions of CYP2B6 with substrates and inactivators/inhibitors and are consistent with the crystal structures.


Subject(s)
Androgens/metabolism , Cytochrome P-450 CYP2B6/genetics , Cytochrome P-450 CYP2B6/metabolism , Androstenedione/metabolism , Binding Sites/drug effects , Binding Sites/genetics , Enzyme Inhibitors/pharmacology , Humans , Hydroxylation , Kinetics , Mutation , Substrate Specificity/drug effects , Substrate Specificity/genetics , Testosterone/metabolism
2.
Chem Res Toxicol ; 28(7): 1484-95, 2015 Jul 20.
Article in English | MEDLINE | ID: mdl-26075493

ABSTRACT

Chlorpyrifos (CPS) is a commonly used pesticide which is metabolized by P450s into the toxic metabolite chlorpyrifos-oxon (CPO). Metabolism also results in the release of sulfur, which has been suggested to be involved in mechanism-based inactivation (MBI) of P450s. CYP2B6 was previously determined to have the greatest catalytic efficiency for CPO formation in vitro. Therefore, we characterized the MBI of CYP2B6 by CPS. CPS inactivated CYP2B6 in a time- and concentration-dependent manner with a kinact of 1.97 min(-1), a KI of 0.47 µM, and a partition ratio of 17.7. We further evaluated the ability of other organophosphate pesticides including chorpyrifos-methyl, diazinon, parathion-methyl, and azinophos-methyl to inactivate CYP2B6. These organophosphate pesticides were also potent MBIs of CYP2B6 characterized by similar kinact and KI values. The inactivation of CYP2B6 by CPS was accompanied by the loss of P450 detectable in the CO reduced spectrum and loss of detectable heme. High molecular weight aggregates were observed when inactivated CYP2B6 was run on SDS-PAGE gels indicating protein aggregation. Interestingly, we found that the rat homologue of CYP2B6, CYP2B1, was not inactivated by CPS despite forming CPO to a similar extent. On the basis of the locations of the Cys residues in the two proteins which could react with released sulfur during the metabolism of CPS, we investigated whether the C475 in CYP2B6, which is not conserved in CYP2B1, was the critical residue for inactivation by mutating it to a Ser. CYP2B6 C475S was inactivated to a similar extent as wild type CYP2B6 indicating that C475 is not likely the key difference between CYP2B1 and CYP2B6 with respect to inactivation. These results indicate that CPS and other organophosphate pesticides are potent MBIs of CYP2B6 which may have implications for the toxicity of these pesticides as well as the potential for pesticide-drug interactions.


Subject(s)
Chlorpyrifos/metabolism , Cytochrome P-450 CYP2B6/metabolism , Insecticides/metabolism , Animals , Chlorpyrifos/chemistry , Chromatography, High Pressure Liquid , Cytochrome P-450 CYP2B1/chemistry , Cytochrome P-450 CYP2B1/metabolism , Cytochrome P-450 CYP2B6/chemistry , Cytochrome P-450 CYP2B6/genetics , Electrophoresis, Polyacrylamide Gel , Heme/metabolism , Humans , Insecticides/chemistry , Kinetics , Mutagenesis, Site-Directed , Protein Binding , Rats , Spectrometry, Mass, Electrospray Ionization
3.
Drug Metab Dispos ; 41(10): 1813-24, 2013 Oct.
Article in English | MEDLINE | ID: mdl-23886699

ABSTRACT

The mechanism-based inactivation of human CYP2B6 by ritonavir (RTV) in a reconstituted system was investigated. The inactivation is time, concentration, and NADPH dependent and exhibits a K(I) of 0.9 µM, a k(inact) of 0.05 min⁻¹, and a partition ratio of approximately 3. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis showed that the protonated molecular ion of RTV exhibits an m/z at 721 and its two major metabolites are an oxidation product with MH⁺ at m/z 737 and a deacylated product with MH⁺ at m/z 580. Inactivation of CYP2B6 by incubation with 10 µM RTV for 10 min resulted in an approximately 50% loss of catalytic activity and native heme, but no modification of the apoprotein was observed. RTV was found to be a potent mixed-type reversible inhibitor (K(i) = 0.33 µM) and a type II ligand (spectral dissociation constant-K(s) = 0.85 µM) of CYP2B6. Although previous studies have demonstrated that RTV is a potent mechanism-based inactivator of CYP3A4, the molecular mechanism responsible for the inactivation has not been determined. Here, we provide evidence that RTV inactivation of CYP3A4 is due to heme destruction with the formation of a heme-protein adduct. Similar to CYP2B6, there is no significant modification of the apoprotein. Furthermore, LC-MS/MS analysis revealed that both CYP3A4 and human liver microsomes form an RTV-glutathione conjugate having a MH⁺ at m/z 858 during metabolism of RTV, suggesting the formation of an isocyanate intermediate leading to formation of the conjugate.


Subject(s)
Aryl Hydrocarbon Hydroxylases/antagonists & inhibitors , Catalysis/drug effects , Cytochrome P-450 CYP3A Inhibitors , Heme/metabolism , Ritonavir/pharmacology , Apoproteins/metabolism , Aryl Hydrocarbon Hydroxylases/metabolism , Cytochrome P-450 CYP2B6 , Cytochrome P-450 CYP3A/metabolism , Glutathione/metabolism , Humans , Microsomes, Liver/drug effects , Microsomes, Liver/enzymology , Microsomes, Liver/metabolism
4.
Methods Mol Biol ; 987: 61-9, 2013.
Article in English | MEDLINE | ID: mdl-23475667

ABSTRACT

The mechanism-based inactivation (MBI) of the human cytochrome P450 (P450 or CYP) drug-metabolizing enzymes may lead to adverse drug-drug interactions, especially for drugs with narrow therapeutic windows. Unlike reversible inhibitors of P450, drug-drug interactions originating from MBI may persist in patients for some time after the body eliminates the offending drug because P450 enzymatic activity can be recovered only after de novo synthesis of the P450. In a pharmaceutical setting, a substantial amount of effort is often expended to understand the potential for mechanism-based inactivation and its possible contribution to the drug-drug interaction profile of drug candidates. Therefore, in vitro assays that identify and characterize which drug candidates are P450 MBIs are critically important in preclinical drug metabolism and pharmacokinetic studies. A detailed method is described for the adaptation of a 7-ethoxytrifluoromethyl coumarin O-deethylation fluorescence activity assay to a 96-well plate format to characterize the K I and k inact values for an MBI. The advantages of this microtiter format compared with the conventional method include a significant reduction in the amount of enzyme used, a reduction in assay time, and an increase in experimental throughput.


Subject(s)
Cytochrome P-450 Enzyme System/metabolism , Drug Evaluation, Preclinical/methods , High-Throughput Screening Assays/methods , Spectrometry, Fluorescence/methods , Animals , Enzyme Activation/drug effects , Humans , Rats
5.
Drug Metab Dispos ; 41(1): 101-10, 2013 Jan.
Article in English | MEDLINE | ID: mdl-23043184

ABSTRACT

Studies in microsomal and reconstituted systems have shown that the presence of one cytochrome P450 isoform can significantly influence the catalytic activity of another isoform. In this study, we assessed whether CYP2E1 could influence the catalytic activity of CYP2B4 under steady-state turnover conditions. The results show that CYP2E1 inhibits CYP2B4-mediated metabolism of benzphetamine (BNZ) with a K(i) of 0.04 µM. However, CYP2B4 is not an inhibitor of CYP2E1-mediated p-nitrophenol hydroxylation. When these inhibition studies were performed with the artificial oxidant tert-butyl hydroperoxide, CYP2E1 did not significantly inhibit CYP2B4 activity. Determinations of the apparent K(M) and k(cat) of CYP2B4 for CPR in the presence of increasing concentrations of CYP2E1 revealed a mixed inhibition of CYP2B4 by CYP2E1. At low concentrations of CYP2E1, the apparent K(M) of CYP2B4 for CPR increased up to 23-fold with virtually no change in the k(cat) for the reaction, however, at higher concentrations of CYP2E1, the apparent K(M) of CYP2B4 for CPR decreased to levels similar to those observed in the absence of CYP2E1 and the k(cat) also decreased by 11-fold. Additionally, CYP2E1 increased the apparent K(M) of CYP2B4 for BNZ by 8-fold and the apparent K(M) did not decrease to its original value when saturating concentrations of CPR were used. While the individual apparent K(M) values of CYP2B4 and CYP2E1 for CPR are similar, the apparent K(M) of CYP2E1 for CPR in the presence of CYP2B4 decreased significantly, thus suggesting that CYP2B4 enhances the affinity of CYP2E1 for CPR and this may allow CYP2E1 to out-compete CYP2B4 for CPR.


Subject(s)
Aryl Hydrocarbon Hydroxylases/metabolism , Cytochrome P-450 CYP2E1/metabolism , NADPH-Ferrihemoprotein Reductase/metabolism , Base Sequence , Catalysis , Cytochrome P450 Family 2 , DNA Primers , Hydroxylation , Substrate Specificity
6.
Drug Metab Dispos ; 40(12): 2256-66, 2012 Dec.
Article in English | MEDLINE | ID: mdl-22936314

ABSTRACT

Selegiline, the R-enantiomer of deprenyl, is used in the treatment of Parkinson's disease. Bupropion, an antidepressant, often used to treat patients in conjunction with selegiline, is metabolized primarily by CYP2B6. The effect of selegiline on the enzymatic activity of human cytochrome CYP2B6 in a reconstituted system and its effect on the metabolism of bupropion were examined. Selegiline was found to be a mechanism-based inactivator of the 7-ethoxy-4-(trifluoromethyl)coumarin O-deethylation (7-EFC) activity of CYP2B6 as well as bupropion metabolism. The inactivations were time-, concentration-, and NADPH-dependent and were characterized by K(I) values of 0.14 and 0.6 µM, k(inact) values of 0.022 and 0.029 min⁻¹, and t(½) values of 31.5 and 24 min, respectively. In standard inhibition assays, selegiline increased the K(m) of CYP2B6 for bupropion from 10 to 92 µM and decreased the k(cat) by ∼50%. The reduced carbon-monoxide difference spectrum revealed over a 50% loss in the cytochrome P450 spectrum in the inactivated sample, with no loss in heme, and there was ∼70% loss in enzyme activity. Trapping of the reactive metabolite using GSH led to the identification of a GSH-selegiline conjugate with a m/z 528 that could be explained by hydroxylation of selegiline followed by the addition of glutathione to the propargyl moiety after oxygenation to form the ketene intermediate. Liquid chromatography-tandem mass spectrometry analysis of the labeled protein following digestion with trypsin revealed the peptide 64DVFTVHLGPR7³ as the peptide modified by the reactive metabolite of selegiline and the site of adduct formation is Asp64.


Subject(s)
Aryl Hydrocarbon Hydroxylases/antagonists & inhibitors , Bupropion/metabolism , Glutathione/metabolism , Oxidoreductases, N-Demethylating/antagonists & inhibitors , Peptides/metabolism , Selegiline/pharmacology , Amino Acid Sequence , Antidepressive Agents, Second-Generation/metabolism , Antiparkinson Agents/pharmacology , Aryl Hydrocarbon Hydroxylases/metabolism , Chromatography, Liquid/methods , Cytochrome P-450 CYP2B6 , Cytochrome P-450 Enzyme Inhibitors , Cytochrome P-450 Enzyme System/metabolism , Drug Interactions , Escherichia coli/metabolism , Heme/metabolism , Humans , Hydroxylation/drug effects , Molecular Sequence Data , NADP/metabolism , Oxidoreductases, N-Demethylating/metabolism , Tandem Mass Spectrometry/methods
7.
Chem Res Toxicol ; 25(12): 2642-53, 2012 Dec 17.
Article in English | MEDLINE | ID: mdl-23016756

ABSTRACT

The reaction of peroxynitrite (PN) with purified human cytochrome P450 3A4 (CYP3A4) resulted in the loss of the reduced-CO difference spectrum, but the absolute absorption spectrum of the heme was not significantly altered. The loss of 7-benzyloxy-4-(trifluoromethyl)coumarin (BFC) O-debenzylation activity of CYP3A4 was concentration-dependent with respect to PN, and the loss of BFC activity supported by NADPH-cytochrome P450 reductase (CPR) was much greater than that supported by tert-butyl hydroperoxide. Moreover, the PN-treated CYP3A4 exhibited a reduced-CO spectrum when reduced by CPR that was much smaller than when it was reduced by dithionite. These results suggest that modification of CYP3A4 by PN may impair its interaction with CPR, leading to the loss of catalytic activity. Tyrosine nitration, as measured by an increase in mass of 45 Da due to the addition of a nitro group, was used as a biomarker for protein modification by PN. PN-treated CYP3A4 was digested by trypsin and endoproteinase Glu C, and nitrotyrosine formation was then determined by using electrospray ionization-liquid chromatography-tandem mass spectrometry. Tyr residues 99, 307, 347, 430, and 432 were found to be nitrated. Using the GRAMM-X docking program, the structure for the CYP3A4-CPR complex shows that Tyr99, Tyr347, and Tyr430 are on the proximal side of CYP3A4 and are in close contact with three acidic residues in the FMN domain of CPR, suggesting that modification of one or more of these tyrosine residues by PN may influence CPR binding or the transfer of electrons to CYP3A4. Mutagenesis of Tyr430 to Phe or Val revealed that both the aromatic and the hydroxyl groups of Tyr are required for CPR-dependent catalytic activity and thus support the idea that the proximal side Tyr participates in the 3A4-CPR interaction. In conclusion, modification of tyrosine residues by PN and their subsequent identification can be used to enhance our knowledge of the structure/function relationships of the P450s with respect to the electron transfer steps, which are critical for P450 activity.


Subject(s)
Cytochrome P-450 CYP3A/metabolism , NADPH-Ferrihemoprotein Reductase/metabolism , Peroxynitrous Acid/metabolism , Tyrosine/analogs & derivatives , Cytochrome P-450 CYP3A/chemistry , Dithionite/metabolism , Humans , Oxidation-Reduction , Peptides/chemistry , Peptides/metabolism , Protein Conformation , Tyrosine/metabolism
8.
Drug Metab Dispos ; 40(5): 998-1006, 2012 May.
Article in English | MEDLINE | ID: mdl-22344702

ABSTRACT

Previous studies have demonstrated that bergamottin (BG), a component of grapefruit juice, is a mechanism-based inactivator of CYP3A4 and contributes, in part, to the grapefruit juice-drug interaction. Although the covalent binding of [(14)C]BG to the CYP3A4 apoprotein has been demonstrated by SDS-polyacrylamide gel electrophoresis, the identity of the modified amino acid residue and the reactive intermediate species of BG responsible for the inactivation have not been reported. In the present study, we show that inactivation of CYP3A4 by BG results in formation of a modified apoprotein-3A4 and a GSH conjugate, both exhibiting mass increases of 388 Da, which corresponds to the mass of 6',7'-dihydroxybergamottin (DHBG), a metabolite of BG, plus one oxygen atom. To identify the adducted residue, BG-inactivated 3A4 was digested with trypsin, and the digests were then analyzed by liquid chromatography-tandem mass spectrometry (MS/MS). A mass shift of 388 Da was used for the SEQUEST database search, which revealed a mass increase of 388 Da for the peptide with the sequence (272)LQLMIDSQNSK(282), and MS/MS analysis of the adducted peptide demonstrated that Gln273 is the residue modified. Mutagenesis studies showed that the Gln273 to Val mutant was resistant to inactivation by BG and DHBG and did not generate two of the major metabolites of BG formed by 3A4 wild type. In conclusion, we have determined that the reactive intermediate, oxygenated DHBG, covalently binds to Gln273 and thereby contributes to the mechanism-based inactivation of CYP3A4 by BG.


Subject(s)
Beverages , Citrus paradisi , Cytochrome P-450 CYP3A Inhibitors , Food-Drug Interactions , Furocoumarins/metabolism , Furocoumarins/pharmacology , Amino Acid Substitution , Apoenzymes/metabolism , Binding Sites , Chromatography, Liquid , Cytochrome P-450 CYP3A/chemistry , Cytochrome P-450 CYP3A/genetics , Electrophoresis, Polyacrylamide Gel , Escherichia coli/genetics , Glutathione/metabolism , Humans , Mutagenesis, Site-Directed , Plasmids , Protein Binding , Spectrometry, Mass, Electrospray Ionization , Tandem Mass Spectrometry
9.
J Pharmacol Exp Ther ; 338(3): 803-9, 2011 Sep.
Article in English | MEDLINE | ID: mdl-21659470

ABSTRACT

In this study, metabolism of bupropion, efavirenz, and 7-ethoxy-4-trifluoromethylcoumarin (7-EFC) by CYP2B6 wild type (CYP2B6.1) and six polymorphic variants (CYP2B6.4 to CYP2B6.9) was investigated in a reconstituted system to gain a better understanding of the effects of the mutations on the catalytic properties of these naturally occurring variants. All six variants were successfully overexpressed in Escherichia coli, including CYP2B6.8 (the K139E variant), which previously could not be overexpressed in mammalian COS-1 cells (J Pharmacol Exp Ther 311:34-43, 2004). The steady-state turnover rates for the hydroxylation of bupropion and efavirenz and the O-deethylation of 7-EFC showed that these mutations significantly alter the catalytic activities of CYP2B6. It was found that CYP2B6.6 exhibits 4- and 27-fold increases in the K(m) values for the hydroxylation of bupropion and efavirenz, respectively, and CYP2B6.8 completely loses its ability to metabolize any of the substrates under normal turnover conditions. However, compared with CYP2B6.1, CYP2B6.8 retains 77% of its 7-EFC O-deethylase activity in the presence of tert-butyl hydroperoxide as an alternative oxidant, indicating that the heme and the active site are catalytically competent. Presteady-state measurements of the rate of electron transfer from NADPH-dependent cytochrome P450 reductase (CPR) to CYP2B6.8 using stopped-flow spectrophotometry revealed that CYP2B6.8 is incapable of accepting electrons from CPR. These observations provide conclusive evidence suggesting that the charge-reversal mutation in the K139E variant prevents CYP2B6.8 from forming a functional complex with CPR. Results from this work provide further insights to better understand the genotype-phenotype correlation regarding CYP2B6 polymorphisms and drug metabolism.


Subject(s)
Anti-HIV Agents/metabolism , Antidepressive Agents, Second-Generation/pharmacokinetics , Aryl Hydrocarbon Hydroxylases/genetics , Benzoxazines/metabolism , Bupropion/metabolism , NADPH-Ferrihemoprotein Reductase/metabolism , Oxidoreductases, N-Demethylating/genetics , Alkynes , Animals , Aryl Hydrocarbon Hydroxylases/metabolism , COS Cells , Catalysis , Chlorocebus aethiops , Coumarins/metabolism , Cyclopropanes , Cytochrome P-450 CYP2B6 , Electron Transport , Escherichia coli/metabolism , Ferric Compounds/metabolism , Genetic Variation , Kinetics , Mutagenesis , Mutation/physiology , Oxidoreductases, N-Demethylating/metabolism , Polymorphism, Genetic , tert-Butylhydroperoxide/metabolism
10.
Biochemistry ; 50(19): 3957-67, 2011 May 17.
Article in English | MEDLINE | ID: mdl-21462923

ABSTRACT

Cytochrome P450 (CYP or P450)-mediated drug metabolism requires the interaction of P450s with their redox partner, cytochrome P450 reductase (CPR). In this work, we have investigated the role of P450 hydrophobic residues in complex formation with CPR and uncovered novel roles for the surface-exposed residues V267 and L270 of CYP2B4 in mediating CYP2B4--CPR interactions. Using a combination of fluorescence labeling and stopped-flow spectroscopy, we have investigated the basis for these interactions. Specifically, in order to study P450--CPR interactions, a single reactive cysteine was introduced in to a genetically engineered variant of CYP2B4 (C79SC152S) at each of seven strategically selected surface-exposed positions. Each of these cysteine residues was modified by reaction with fluorescein-5-maleimide (FM), and the CYP2B4-FM variants were then used to determine the K(d) of the complex by monitoring fluorescence enhancement in the presence of CPR. Furthermore, the intrinsic K(m) values of the CYP2B4 variants for CPR were measured, and stopped-flow spectroscopy was used to determine the intrinsic kinetics and the extent of reduction of the ferric P450 mutants to the ferrous P450--CO adduct by CPR. A comparison of the results from these three approaches reveals that the sites on P450 exhibiting the greatest changes in fluorescence intensity upon binding CPR are associated with the greatest increases in the K(m) values of the P450 variants for CPR and with the greatest decreases in the rates and extents of reduced P450--CO formation.


Subject(s)
Cytochrome P-450 Enzyme System/chemistry , Hydrophobic and Hydrophilic Interactions , Leucine/chemistry , NADPH-Ferrihemoprotein Reductase/chemistry , Valine/chemistry , Animals , Aryl Hydrocarbon Hydroxylases/chemistry , Aryl Hydrocarbon Hydroxylases/genetics , Cytochrome P-450 Enzyme System/genetics , Cytochrome P450 Family 2 , Leucine/genetics , Mutagenesis, Site-Directed , NADPH-Ferrihemoprotein Reductase/genetics , Rats , Spectrometry, Fluorescence , Surface Properties , Valine/genetics
11.
Arch Biochem Biophys ; 507(1): 135-43, 2011 Mar 01.
Article in English | MEDLINE | ID: mdl-20836985

ABSTRACT

Cytochromes P450 (CYPs or P450s) contain a highly conserved threonine residue in the active site, which is referred to as Thr302 in the amino acid sequence of CYP2B4. Extensive biochemical and crystallographic studies have established that this Thr302 plays a critical role in activating molecular oxygen to generate Compound I, a putative iron(IV)-oxo porphyrin cation radical, that carries out the preliminary oxygenation of CYP substrates. Because of its proximity to the center of the P450 active site, this Thr302 is susceptible to mechanism-based inactivation under certain conditions. In this article, we review recent studies on the mechanism-based inactivation of three mammalian P450s in the 2B family, CYP2B1 (rat), 2B4 (rabbit) and 2B6 (human) by tert-butylphenylacetylene (tBPA). These studies showed that tBPA is a potent mechanism-based inactivator of CYP2B1, 2B4 and 2B6 with high k(inact)/K(I) ratios (0.23-2.3min(-1)µM(-1)) and low partition ratios (0-5). Furthermore, mechanistic studies revealed that tBPA inactivates these three CYP2B enzymes through the formation of a single ester adduct with the Thr302 in the active site. These inhibitory properties of tBPA allowed the preparation of a modified CYP2B4 where the Thr302 was covalently and stoichiometrically labeled by a reactive intermediate of tBPA in quantities large enough to permit spectroscopic and crystallographic studies of the consequences of covalent modification of Thr302. Molecular modeling studies revealed a unique binding mode of tBPA in the active site that may shed light on the potency of this inhibition. The results from these studies may serve as a basis for designing more specific and potent inhibitors for P450s by targeting this highly conserved threonine residue which is present in the active sites of most mammalian P450s.


Subject(s)
Acetylene/analogs & derivatives , Cytochrome P-450 Enzyme Inhibitors , Cytochrome P-450 Enzyme System/metabolism , Threonine/metabolism , Acetylene/chemistry , Acetylene/metabolism , Amino Acid Sequence , Animals , Aryl Hydrocarbon Hydroxylases/antagonists & inhibitors , Aryl Hydrocarbon Hydroxylases/chemistry , Aryl Hydrocarbon Hydroxylases/metabolism , Catalytic Domain , Cytochrome P-450 Enzyme System/chemistry , Humans , Models, Molecular , Molecular Sequence Data , Protein Binding , Substrate Specificity , Threonine/chemistry
12.
Nat Protoc ; 5(10): 1652-8, 2010 Sep.
Article in English | MEDLINE | ID: mdl-20885377

ABSTRACT

Mechanism-based inactivators such as bergamottin are useful chemical tools for identifying the functions of specific active-site amino acid residues in the reactions catalyzed by cytochromes P450 (CYPs or P450s), which are responsible for the metabolism of a wide variety of drugs and endogenous substrates. In clinical settings, mechanism-based inactivation of P450s involved in xenobiotic metabolism has the potential to lead to adverse drug-drug interactions, and assays to identify and characterize drug candidates as P450 inactivators are important in drug discovery and development. Here we present a quantitative high-throughput protocol for investigating cytochrome P450 mechanism-based inactivators; we use the example of CYP2B6 and bergamottin to illustrate the finer points of this protocol. This protocol details the adaptation of a 7-ethoxytrifluoromethyl coumarin O-deethylation fluorescence activity assay to a 96-well microtiter plate format and uses a plate reader to detect the fluorescence of the product. Compared with previous methods, this protocol requires less P450 and takes significantly less time while greatly increasing throughput. The protocol as written takes ∼2 h to complete. The principles and procedures outlined in this protocol can be easily adapted to other inactivators, P450 isoforms, substrates and plate readers.


Subject(s)
Aryl Hydrocarbon Hydroxylases/antagonists & inhibitors , Cytochrome P-450 Enzyme Inhibitors , High-Throughput Screening Assays/methods , Oxidoreductases, N-Demethylating/antagonists & inhibitors , Amino Acids/chemistry , Aryl Hydrocarbon Hydroxylases/metabolism , Coumarins/chemistry , Cytochrome P-450 CYP2B6 , Cytochrome P-450 Enzyme System/metabolism , Enzyme Inhibitors/chemistry , Fluorescent Dyes , Fluorometry/methods , Furocoumarins/chemistry , Humans , Oxidoreductases, N-Demethylating/metabolism , Time Factors
13.
J Biol Chem ; 284(38): 25678-86, 2009 Sep 18.
Article in English | MEDLINE | ID: mdl-19605359

ABSTRACT

The conformational dynamics of cytochrome P450 2B1 (CYP2B1) were investigated through the introduction of a disulfide bond to link the I- and K-helices by generation of a double Cys variant, Y309C/S360C. The consequences of the disulfide bonding were examined both experimentally and in silico by molecular dynamics simulations. Under high hydrostatic pressures, the partial inactivation volume for the Y309C/S360C variant was determined to be -21 cm3mol(-1), which is more than twice as much as those of the wild type (WT) and single Cys variants (Y309C, S360C). This result indicates that the engineered disulfide bond has substantially reduced the protein plasticity of the Y309C/S360C variant. Under steady-state turnover conditions, the S360C variant catalyzed the N-demethylation of benzphetamine and O-deethylation of 7-ethoxy-trifluoromethylcoumarin as the WT did, whereas the Y309C variant retained only 39% of the N-demethylation activity and 66% of the O-deethylation activity compared with the WT. Interestingly, the Y309C/S360C variant restored the N-demethylation activity to the same level as that of the WT but decreased the O-deethylation activity to only 19% of the WT. Furthermore, the Y309C/S360C variant showed increased substrate specificity for testosterone over androstenedione. Molecular dynamics simulations revealed that the engineered disulfide bond altered substrate access channels. Taken together, these results suggest that protein dynamics play an important role in regulating substrate entry and recognition.


Subject(s)
Androsterone/chemistry , Cytochrome P-450 CYP2B1/chemistry , Disulfides/chemistry , Mutation, Missense , Testosterone/chemistry , Amino Acid Substitution , Cytochrome P-450 CYP2B1/genetics , Humans , Protein Structure, Secondary , Substrate Specificity/genetics
SELECTION OF CITATIONS
SEARCH DETAIL
...